Barclays
MREO

Barclays’s Mereo BioPharma MREO Stock Holding History

Barclays’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,600
Closed -$2.33K – 5291
2025
Q4 		$2.33K Hold
5,600
– – ﹤0.01% 5035
2025
Q3 		$11.5K Buy
+5,600
New +$10.3K ﹤0.01% 5007

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Barclays's MREO Position: Q2 2026 in Review

Barclays sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 2,496 shares — an estimated $824 sold.

Barclays first reported a position in MREO in Q2 2019 and held it in 18 quarters. The position peaked at $596K in Q4 2021. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • Barclays reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
  • Barclays sold 2,496 Mereo BioPharma shares in Q2 2026, an estimated $824.
  • Barclays first reported a position in Mereo BioPharma in Q2 2019 and held it in 18 quarters.
  • Barclays's Mereo BioPharma position peaked at $596K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.